Parker Jenkins wanted to show off his magnet. In a LinkedIn post last spring, the co-founder of Adialante—a four-person startup working out of Redwood City—shared photos of what he called the company's "full preclinical magnet." It looked less like a breakthrough and more like industrial machinery awaiting assembly. Which, in a sense, it was.
But in the world of magnetic resonance imaging, where hardware development timelines stretch on and capital requirements can sink entire companies, that magnet represented something: tangible progress. And perhaps a bet that the entrenched economics of MRI—long the province of hospital radiology departments and multimillion-dollar installations—might be shifting, according to a growing chorus of industry observers and startups targeting the space.
The problem Adialante is chasing isn't new. Early cancer detection can mean the difference between a five-year survival rate near 100% and something far grimmer. Yet across the United States, access to the advanced imaging that makes such detection possible remains stubbornly uneven, shaped by geography, income, and a web of operational constraints. A handful of startups now believe they can change that equation—armed with new approaches to MRI hardware and business models borrowed from mobile clinics. Whether they succeed is another question entirely.
Mobile Scans, Flat Fees, and a Prostate Play
Adialante emerged from the University of Minnesota's biomedical engineering labs and joined Y Combinator's cohort earlier this year. The company is developing what it describes as a mobile, diagnostic-quality MRI system designed to deliver cancer screening—initially focused on pre-biopsy prostate imaging—at a fraction of traditional costs. The pitch sounds familiar if you've heard enough startup decks: eliminate the barriers keeping patients from scans in the first place, whether those barriers are wait times, travel distance, or price opacity.
The go-to-market strategy centers on mobility and per-scan pricing. Rather than selling capital equipment to hospitals, Adialante plans to deploy its imaging system in a mobile clinic format—essentially, a truck with the MRI onboard—and charge a flat fee per scan. It's a model already proven by companies like RAYUS Radiology, which provides mobile MRI services on per-scan or contract terms. Adialante's twist is the focus on cancer screening and a claimed cost structure significantly below standard MRI.
The company had pulled together roughly $3 million in funding as of June 2025, according to available disclosures—including a $1.18 million NSF SBIR Phase II grant that began in June 2025. It holds two issued U.S. patents and has backing from Brown Venture Group alongside the NSF and Y Combinator support. CEO Efraín Torres, who holds a PhD in biomedical engineering from the University of Minnesota and previously led academic work on portable, low-cost MRI, testified to the Minnesota legislature in 2023 about developing affordable MRI technology to expand access.
Adialante's Y Combinator profile makes a bold assertion: that early detection can improve outcomes "8–10x"—a claim the company bases on the dramatic survival differences between localized and distant-stage cancers, though the extent to which this multiplier applies uniformly across all cancer types and populations remains a matter of clinical debate. SEER data for prostate cancer, for example, shows five-year relative survival near 100% for localized disease versus markedly lower rates for metastatic cases. Breast cancer survival similarly diverges sharply by stage. The American College of Radiology has been careful to underscore the complexity of these claims. In 2023, the ACR issued a statement cautioning against whole-body MRI for asymptomatic individuals without high-risk factors, citing concerns about false positives and downstream costs.
Adialante is focusing initially on prostate—a more defensible beachhead, clinically speaking. Pre-biopsy prostate MRI is increasingly embedded in diagnostic pathways, reimbursed by payers when medically indicated, and supported (with caveats) by clinical guidelines.
The Access Gap Nobody Fixed
The global MRI systems market sits somewhere around $7 billion to $8.6 billion, depending on which market research firm you ask, with projections for compound annual growth around 6% through the mid-2030s. That growth, however, masks persistent inequities. OECD data shows wide variation in MRI unit density per capita across developed nations. Wait times for scans can stretch weeks or months in underserved regions. A Lancet Oncology Commission report from 2021, still cited frequently within the imaging community, estimated that scaled access to diagnostic imaging could avert 2.5 million cancer deaths globally by 2030.
In the United States, the adoption of pre-biopsy prostate MRI illustrates both progress and gaps. A Blue Cross Blue Shield claims analysis covering 2016 through 2022 found that use of MRI before prostate biopsy climbed from 9.5% to 33.2%—evidence that urologists and radiologists are embracing multiparametric MRI to reduce unnecessary biopsies and improve detection of clinically significant cancer. The approach is supported by randomized trials like PRECISION, published in 2018 and subsequently corroborated by additional studies, showing that MRI-targeted pathways cut negative biopsy rates and spare patients invasive procedures. The American Urological Association's 2023 early detection guidelines include MRI, though with nuance around evidence strength for biopsy-naïve men.
But the same Blue Cross analysis revealed sharp socioeconomic and geographic disparities—metro areas outpacing non-metro, insured populations faring better than those without coverage. For a technology that requires specialized infrastructure, trained radiologists, and (traditionally) costly siting and maintenance, these imbalances are structural, not incidental. They're also the kind of thing that tends to persist unless someone rewrites the economics.
What Changed: Helium, AI, and the Low-Field Rebellion
Several converging trends are reshaping the MRI hardware landscape, creating openings that startups like Adialante hope to exploit.
Helium volatility has become a strategic concern. Conventional high-field MRI magnets rely on liquid helium for superconducting coil cooling, but helium supply has cycled through shortages—industry commentary in 2026 refers to "Shortage 4.0," which tells you something about the recurring nature of the problem. That volatility increases operational risk and lifecycle costs. In response, manufacturers have rolled out helium-free or helium-light designs.
Philips's BlueSeal platform, which seals a small volume of helium permanently, reportedly had more than 2,200 1.5T systems installed globally by April of this year, saving over six million liters of helium to date. At RSNA late last year, Philips unveiled BlueSeal Horizon, billed as the industry's first helium-free 3.0T system. Siemens Healthineers' Magnetom Free family operates at 0.55 Tesla using roughly 0.7 liters of sealed helium; in January the company introduced the Free.XL variant for interventional workflows.
These low-helium and lower-field-strength platforms offer siting flexibility—less weight, reduced infrastructure demands, fewer ongoing costs. The upshot: MRI becomes feasible in settings where traditional magnets would be impractical or unaffordable.
Artificial intelligence is accelerating workflow and image quality improvements, sometimes dramatically. GE HealthCare's AIR Recon DL, for instance, claims to cut exam times up to 50% through deep-learning reconstruction. Philips has deployed Compressed SENSE and SmartSpeed Precise across its systems; Siemens is embedding Deep Resolve reconstruction in its low-field platforms. Academic papers published over the past year or so demonstrate feasibility of functional MRI at 0.55T and novel reconstruction techniques that narrow image-quality gaps between low-field and high-field systems.
These advances matter because they shift the cost-benefit calculus. If a lighter, cheaper magnet can deliver diagnostic images in less time, the operational case for distributed, mobile, or office-based MRI strengthens considerably.
Portable and ultra-low-field MRI has moved from research curiosity to commercial reality, though the jury's still out on adoption. Hyperfine's Swoop, a 0.064T portable brain MRI that received FDA clearance in 2020, announced first commercial sales of its next-generation system with Optive AI last summer and reported progress toward neurology office markets in a March investor update. The UNITY Project, funded by the Bill & Melinda Gates Foundation, deployed around 30 Hyperfine units across low- and middle-income countries to standardize protocols and training—generating operational lessons and use-case evidence in settings from Malawi pediatric wards to academic centers.
Other niche players have established footholds. Promaxo received FDA 510(k) clearance in 2021 for an in-office prostate MRI system operating at very low field strength, targeting urologists who want to integrate imaging directly into biopsy workflows. Synaptive's Evry (0.5T head MRI, cleared in 2020) serves point-of-care neurology and ICU applications. Aspect Imaging's Embrace (1.0T neonatal head MRI, cleared in 2017) sits in NICUs to eliminate transport risks for fragile infants.
Technical Gambles and Business Model Bets
Adialante enters this landscape with a specific technical and business model wager. According to its NSF SBIR award description, the company's approach uses "B1 encoding" to eliminate or reduce reliance on conventional gradient coils—components that add cost, weight, and complexity. The initial concept targets head imaging, though the company's public roadmap spans prostate, musculoskeletal, breast, renal, and neuro applications. That's an ambitious list for a four-person team.
The company's mission framing, articulated in an April post by Fogarty Innovation, emphasizes that "early cancer detection shouldn't be dictated by geography or income." It's a message that resonates with the current zeitgeist around health equity. Whether it translates into diagnostic images, regulatory clearance, and a scalable business is the harder question.
The competitive landscape includes both established imaging giants pivoting to flexibility and startups targeting specific niches. Siemens and Philips are deploying low-helium systems with compelling operational advantages but still primarily through traditional capital-sale channels to hospitals and imaging centers. Hyperfine is carving out point-of-care neuro applications with mixed results.
Then there's a different breed of competitor: companies like Ezra and Prenuvo, which are pursuing consumer-facing whole-body MRI screening. Ezra announced FDA clearances in March for its "Ezra Flash" AI and prostate AI, aiming for 15-minute, $500 scans. Prenuvo raised $120 million in early 2025 and opened its first European clinic in London in March. Both operate on third-party MRI hardware in fixed locations, offering a direct-pay screening service without the guideline endorsements that would bring payer coverage. They're betting consumers will pay out-of-pocket for peace of mind; Adialante is betting it can slot into existing diagnostic and reimbursement pathways.
Adialante's challenge is multifaceted: deliver diagnostic image quality at low field strength (likely leveraging AI reconstruction), navigate FDA 510(k) clearance as a Class II medical device (MRI systems fall under 21 CFR 892.1000), prove clinical utility in head-to-head comparisons with standard-of-care imaging, and build a mobile service operation that can achieve unit economics at scale. All while addressing a market segment—screening—where payer coverage and guideline support remain uncertain outside specific indications.
That's a lot of ifs.
Fragmentation, Flexibility, and the Incumbents' Response
The MRI hardware market is entering a period of architectural fragmentation. For decades, the industry converged on higher field strengths—1.5T and 3.0T—optimizing for image quality and speed. Now helium economics, siting constraints, and the push for access are pulling in another direction: toward lighter, lower-cost, more portable systems that trade some image fidelity for operational flexibility, with AI and advanced reconstruction techniques narrowing the quality gap.
This divergence creates space for startups. A company like Adialante doesn't need to outperform a 3.0T Siemens magnet in image resolution; it needs to deliver "good enough" images for specific clinical decisions—say, identifying PI-RADS 4 or 5 lesions in the prostate—at a price point and convenience level that changes utilization patterns. If a mobile unit can park outside a urology clinic in a rural area and scan patients for a fraction of what a hospital charges, the access equation shifts.
But the path is littered with regulatory, clinical, and commercial hurdles. The FDA's Quality Management System Regulation (QMSR), which went into effect in February and aligns U.S. standards with ISO 13485:2016, sets a higher bar for device manufacturers' quality systems. Adialante will need to navigate 510(k) clearance, likely requiring clinical data to establish substantial equivalence to a predicate device. The company's NSF SBIR award runs through November—a timeline that suggests preclinical hardware validation is still underway. Translation: they're not scanning patients yet.
Payer reimbursement for "screening MRI" remains ambiguous. Diagnostic MRI—ordered by a physician based on clinical suspicion—is covered. Population-wide screening MRI, absent guideline endorsement, is not. Adialante's strategy of starting with prostate pre-biopsy imaging is savvy in this regard: it slots into an existing diagnostic pathway rather than asking payers to fund speculative whole-body scans.
Longer-term, the success of mobile, low-cost MRI for cancer screening will hinge on outcomes data. Does earlier detection via more accessible imaging actually improve survival and quality of life in real-world populations, net of overdiagnosis and false positives? The Lancet Oncology Commission's 2.5 million lives projection assumes scaling imaging capacity in settings where access is currently near zero. In the U.S., where MRI density is already relatively high but unevenly distributed, the benefit may be more incremental—closing gaps rather than opening new frontiers.
The broader imaging industry is watching. If Adialante or others prove the model, expect established players to respond—and quickly. Siemens and Philips already offer low-field, flexible-siting systems; packaging them in a mobile service model is an operational pivot, not a technology leap. The question is whether the incumbents move fast enough, or whether the startup wedge of focus, speed, and risk tolerance creates defensible market share before the giants fully engage.
For now, Adialante has a preclinical magnet, a team of four, backing from Y Combinator, and a mission statement that resonates with the moment. What remains to be seen is whether that translates into diagnostic images, regulatory clearance, clinical validation, and a business that can scale. The technology trends are favorable. The market need is real.
The execution, as ever, is everything.
